Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Macular Diseases

Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data

Acta Ophthalmol

Karunainathan MG, Lee C, Zohalinejad KD, Mæng MO, Fabrin NW, Jónsdóttir S, Hassing AK, Yde SK, Wykoff CC, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1111/aos.70160

Retinal Diseases

Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study

Sci Rep

Song JR, Jeon J, Baek SC, Sharma A, Sagong M, Lee CS, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group)

doi: 10.1038/s41598-026-52212-4

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Retinal Diseases

Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials

Ophthalmol Retina

Sharma S, Dhoot DS, Grewal DS, Jung E, Silva FQ, Du W, Moini H, Boyer DS

doi: 10.1016/j.oret.2026.04.027

Macular Diseases

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Retina

Lee C, Karunainathan MG, Zohalinejad KD, Mæng MO, Fabrin NW, Yde SK, Wykoff CC, Abildgaard SK, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1097/IAE.0000000000004888

Macular DiseasesRetinal Diseases

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Ophthalmol Ther

Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N

doi: 10.1007/s40123-026-01442-w

Retinal Diseases

Development and Validation of Simple Clinical and OCT-Based Prognostic Scores for Visual Outcomes in Branch Retinal Vein Occlusion

Ophthalmol Retina

Sano H, Yanai R, Kondo H, Misaki T, Nagasato D, Tabuchi H, Mitamura Y

doi: 10.1016/j.oret.2026.07.006

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Further Publications

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis

Retina

Sather RN 3rd, Chiang T, Moon JY, Dev S, Belin PJ

doi: 10.1097/IAE.0000000000004813

Related content

Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data

Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Development and Validation of Simple Clinical and OCT-Based Prognostic Scores for Visual Outcomes in Branch Retinal Vein Occlusion

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis